Recommended Daily Senna Dosing for Constipation
Start with 8.6–17.2 mg (1–2 tablets) of senna taken once nightly at bedtime, and titrate upward only if needed to achieve one non-forced bowel movement every 1–2 days, with a maximum dose of approximately 30 mg daily (3–4 tablets) for most patients. 1, 2
Initial Dosing Strategy
Begin therapy with the lowest effective dose of 8.6–17.2 mg (equivalent to 1–2 standard tablets containing approximately 8–9 mg sennosides each) taken at bedtime to allow the 6–12 hour onset of action to produce a morning bowel movement. 1, 2
The FDA-approved liquid formulation provides 2–3 teaspoons (10–15 mL) once daily as the usual adult dose, with a maximum of 3 teaspoons (15 mL) twice daily. 3
Do not start at the 1 gram daily dose used in clinical trials, as this is 10–12 times higher than standard therapeutic dosing and caused 83% of trial participants to reduce their dose due to abdominal cramping and diarrhea. 1, 2
Dose Titration and Monitoring
If the patient does not achieve at least one spontaneous bowel movement every 1–2 days, increase the dose by 8.6–17.2 mg (1–2 tablets) every 1–2 weeks based on response. 1, 2
Watch for dose-dependent adverse effects including abdominal cramping, pain, or diarrhea, which signal the need to reduce the dose immediately. 1, 2
The generally recommended maximum is 4 tablets twice daily (approximately 68.8 mg per day), though most individuals respond to lower amounts. 1
Special Population Considerations
Palliative Care and Opioid-Induced Constipation
In palliative care settings for patients with weeks to days of life expectancy, higher doses may be used: 2–3 tablets two to three times daily (BID-TID), with a goal of one non-forced bowel movement every 1–2 days. 4, 1
For opioid-induced constipation, provide prophylactic treatment with senna when initiating opioid therapy, and increase the laxative dose proportionally when increasing opioid doses, as constipation does not resolve with tolerance. 4, 5
Elderly Patients
- For elderly patients with constipation unresponsive to senna, escalate to polyethylene glycol (PEG) 17 g once daily rather than increasing senna further, as PEG has a superior safety profile for long-term use in this population. 1, 5
Duration of Therapy
While clinical trials evaluated senna for only 4 weeks, longer-term use is appropriate for chronic constipation management provided patients are periodically reassessed every 3–6 months. 1, 2
The American Gastroenterological Association conditionally recommends senna for chronic idiopathic constipation, though it is primarily intended for short-term or rescue therapy rather than continuous long-term treatment. 1, 2
Combination Therapy Algorithm
When senna monotherapy fails after 1–2 weeks at optimized doses, add polyethylene glycol (PEG) 17 g once daily rather than further increasing the senna dose. 1, 2
If the combination of senna plus PEG remains inadequate after 24–48 hours, add bisacodyl 5–10 mg for short-term rescue therapy. 1, 5
For refractory cases after optimized combination therapy, consider prescription secretagogues such as lubiprostone, linaclotide, or plecanatide. 1, 2
Critical Safety Considerations and Contraindications
Absolute contraindications include intestinal obstruction or ileus, severe dehydration, and acute inflammatory bowel disease (Crohn's disease or ulcerative colitis). 1, 2
Senna is not recommended during pregnancy due to potential weak genotoxic effects observed in animal studies. 1
Concomitant antibiotic therapy can diminish senna's effectiveness by disrupting the gut microbiota required to convert sennosides A and B into their active metabolites (rheinanthrone and rhein). 1, 2
Rule out mechanical obstruction before initiating treatment, and perform a digital rectal exam to exclude fecal impaction if constipation persists despite therapy. 5
Common Pitfalls to Avoid
Avoid initiating therapy at excessive doses: The trial dose of 1 g daily commonly leads to intolerable cramping and diarrhea and should never be used in clinical practice. 1, 2
Do not rely on senna alone for opioid-induced constipation without prophylactic initiation at the start of opioid therapy, as waiting for constipation to develop causes unnecessary suffering. 4, 5
Avoid using bulk laxatives (psyllium/Metamucil) for opioid-induced constipation, as they are ineffective and may worsen symptoms. 4, 5
In patients with chronic kidney disease, avoid magnesium-based laxatives due to hypermagnesemia risk; senna is safe as over 90% is excreted in feces. 1, 2